CoMind: An Innovative Non-Invasive Brain Monitoring Device

CoMind is developing an advanced non-invasive neuromonitoring device, based on lidar-like technology, with significant funding.

CoMind: An Innovative Non-Invasive Brain Monitoring Device
Diagram of CoMind's non-invasive brain monitoring system with infrared technology

Innovation in Brain Monitoring

CoMind, a London-based neurotech startup, is developing a non-invasive brain monitoring device based on lidar-like technology. The system uses advanced infrared light to provide real-time information on cerebral perfusion, autoregulation and intracranial pressure. The device, designed as a simple adhesive sensor placed on the patient's forehead, aims to be easy to use with minimal training.

Clinical Applications and Goals

The main goal is to support clinicians in managing critical conditions such as cardiac surgery, intensive care and treatment of brain trauma. The ability to display brain signals on dedicated screens or integrated systems makes it easy to fit seamlessly into existing workflows, offering truly innovative support. The technology aims to reduce neurosurgical complications through continuous and precise monitoring.

Funding and Development

CoMind recently raised $60 million, led by investors such as Plural, bringing its total investment to over $102 million. The startup plans to begin commercializing the product in 2027, with a strong focus on industrial and clinical applications, aiming to significantly improve the safety and effectiveness of neurological procedures.

Advantages and Future Prospects

The proposed technology could change the way brain functions are monitored, shortening diagnosis times and improving clinical outcomes. Ease of use and integration with existing systems are the keys to CoMind's commercial success, as the company aims to dominate the emerging market for non-invasive neuromonitoring devices.

Key Takeaways

  • CoMind is developing an innovative brain monitoring device based on lidar-like technology.
  • The system uses a simple, smart adhesive sensor, with applications in medicine and research.
  • The recent $60 million funding supports development and the planned commercial launch in 2027.
  • The device promises to improve safety, effectiveness and diagnosis times in neurosurgery and intensive care.